Congratulations to the team at Alesta Therapeutics on raising an impressive €65 million in their Series A financing! Led by Frazier Life Sciences and Droia Ventures, this round will push their work in rare disease therapies to new levels.
Their lead program, ALE1, targets hypophosphatasia (HPP), a rare genetic disorder, with plans to enter clinical trials in 2025. With a second program addressing Charcot-Marie-Tooth (CMT), Alesta is on a mission to transform patient care in underserved areas.
This milestone shows how innovative science, dedicated leadership, and collaboration with global experts lead to impactful results.
We’re excited to see how this funding accelerates their work to deliver life-changing therapies. And we’re proud to see a company in our community thrive on its journey to make a difference in patients’ lives globally.
Huge congrats to the Alesta team and their partners for this incredible achievement!
Read the full press release here
Last week, demissionary Minister of Social Affairs and Employment Eddy van Hijum paid a visit last week to the Post-COVID Expertise Center at Leiden University Medical Center...
Looking for something thoughtful to tune into this summer? Biopolis – Into the Microbiome is a new science podcast blending documentary storytelling with fiction to explore the...
Leiden Bio Science Park is taking concrete steps to increase biodiversity across its grounds, moving beyond ornamental landscaping to create habitats that support a wide range of...